Apimeds Pharmaceuticals US, Inc. 8-K/A

What Happened

• Apimeds Pharmaceuticals US, Inc. (APUS) filed an amendment to its Form 8-K on February 17, 2026, concerning Item 2.01 — the completion of an acquisition or disposition of assets that was reported in an earlier (Original) 8-K.
• The amendment states it does not reflect any events occurring after the Original Report and does not amend or update any disclosures in that Original Report except as expressly provided in the amendment. Item 9.01 (Financial Statements and Exhibits) is also reported in the amendment.

Key Details

• Item reported: 2.01 — Completion of Acquisition or Disposition of Assets (amendment to Original Report).
• Additional item: 9.01 — Financial Statements and Exhibits included or updated in the amendment.
• Filing date: Amended Form 8-K filed February 17, 2026.
• Scope: Amendment does not introduce new post-Original-Report events or change prior disclosures except where explicitly stated.

Why It Matters

• This filing confirms the company’s previously reported asset transaction remains as disclosed in the Original 8-K; no new material events or changes were introduced by the amendment.
• Investors should review the Original Form 8-K and the exhibits referenced in this amendment for transaction terms, financial effects, and any new exhibits or financial statements added here.
• The amendment itself does not signal additional financial results or management changes—its primary purpose is to supplement the record for the completed transaction.